Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer:A systematic review and meta-analysis

: To evaluate overall survival(OS) and biochemical recurrence-free survival (BCRFS) of androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer. Condition being studied: Prostate cancer(PC) is the second most common cancer and the fifth leading cause of cancer death among men wordwide. Radiotherapy(RT) alone may not be effective for treating PC and RT combining wih androgen deprivation therapy(ADT) is often a requisite. For low-risk PC, RT alone has shown high clinical response but for intermediate and high-risk PC, ADT is necessary for clinical effects. Therefore, in this study, we compared the efficacy and safety of RT alone with RT+ADT in intermediate PC through meta analysis, so as to provide evidence-based evidence for the treatment of intermediate PC patients.